Get the Stockscreener App
2.36
7.76%
0.17
Immunitybio Inc stock is traded at $2.36, with a volume of 24.73M.
It is up +7.76% in the last 24 hours and up +14.56% over the past month.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
See More
Previous Close:
$2.19
Open:
$2.29
24h Volume:
24.73M
Relative Volume:
2.42
Market Cap:
$2.32B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-2.433
EPS:
-0.97
Net Cash Flow:
$-425.62M
1W Performance:
+3.06%
1M Performance:
+14.56%
6M Performance:
-26.02%
1Y Performance:
-22.37%
1-Day Range:
$2.25
$2.50
1-Week Range:
$2.17
$2.50
52-Week Range:
$1.83
$4.27
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.36 | 2.16B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
Immunitybio Inc Stock (IBRX) Latest News
Should EMA’s Conditional Nod for ANKTIVA in High-Risk Bladder Cancer Require Action From ImmunityBio (IBRX) Investors? - Yahoo Finance
ImmunityBio, Inc. (NASDAQ:IBRX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
ImmunityBio (NASDAQ:IBRX) Shares Gap UpHere's Why - MarketBeat
ImmunityBio (IBRX) Climbs 7.76% on Europe Expansion - Insider Monkey
D. Boral Capital Maintains ImmunityBio (IBRX) Buy Recommendation - Nasdaq
Jefferies Maintains ImmunityBio (IBRX) Buy Recommendation - Nasdaq
ImmunityBio Gains Momentum: Bladder Cancer Care Focus - StocksToTrade
ImmunityBio, Moderna among winners of EU drug recommendations this week - MSN
Jefferies raises Immunitybio stock price target to $9 on European regulatory progress - Investing.com
ImmunityBio Moves Closer To EU Approval For Bladder Cancer Therapy - Benzinga
CHMP recommends Immunitybio's Anktiva, Cytokinetics' Myqorzo - BioWorld MedTech
Immunitybio stock rises after positive EMA recommendation for bladder cancer therapy - Investing.com Australia
Is ImmunityBio Inc a good long term investmentSector Rotation Strategies & Achieve Consistent Profits - earlytimes.in
ImmunityBio Says European Medicines Agency Recommends Conditional Marketing Authorization for Anktiva with BCG for Non-Muscle Invasive Bladder Cancer - marketscreener.com
ImmunityBio Receives EMA Recommendation for ANKTIVA in Europe - TradingView — Track All Markets
ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe - Business Wire
Armistice Capital LLC Acquires New Position in ImmunityBio, Inc. $IBRX - MarketBeat
10 Big Names Leaving Wall Street in the Dust; 4 at Fresh Highs - Insider Monkey
D. Boral Capital Reiterates "Buy" Rating for ImmunityBio (NASDAQ:IBRX) - MarketBeat
Does Anktiva-Driven Revenue Momentum Reshape the Bull Case For ImmunityBio (IBRX)? - Sahm
ImmunityBio, Inc. (IBRX): A Bull Case Theory - Finviz
ImmunityBio, Inc. (IBRX): A bull case theory - MSN
Can ImmunityBio Stock Hold Up When Markets Turn? - Trefis
Is ImmunityBio Inc. stock a smart buy before Fed meeting2025 Price Targets & Safe Entry Zone Tips - Newser
Will ImmunityBio Inc. (26CA) stock benefit from mergersJuly 2025 Price Swings & Breakout Confirmation Alerts - Newser
How ImmunityBio Inc. (26CA) stock responds to bond marketJuly 2025 Drop Watch & Intraday High Probability Alerts - Newser
Piper Sandler Remains a Buy on ImmunityBio (IBRX) - The Globe and Mail
ImmunityBio Earnings Notes - Trefis
Is ImmunityBio Inc. (26CA) stock undervalued at current priceWeekly Profit Recap & Reliable Volume Spike Trade Alerts - Newser
ImmunityBio (NASDAQ:IBRX) Trading Down 5.4%Should You Sell? - MarketBeat
Lawmakers Invited to FDA Meeting for Soon-Shiong’s Drug - Bloomberg.com
ImmunityBio (IBRX) Slashes 9% on Lack of Leads - Finviz
Lawmakers Invited to FDA Meeting for Patrick Soon-Shiong’s Drug - Bloomberg.com
A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs (NASDAQ:IBRX) - Seeking Alpha
Is ImmunityBio Inc. (IBRX) The Best US Stock To Buy Under $20? - MSN
ImmunityBio (IBRX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
ImmunityBio (NASDAQ:IBRX) Sees Large Volume IncreaseStill a Buy? - MarketBeat
ImmunityBio Stock Rises Despite Financial Challenges - timothysykes.com
Can ImmunityBio Inc. (26CA) stock sustain free cash flowRisk Management & Reliable Volume Spike Trade Alerts - Newser
Geode Capital Management LLC Acquires 1,487,849 Shares of ImmunityBio, Inc. $IBRX - MarketBeat
Assessing ImmunityBio After Recent Cancer Immunotherapy Headlines and Ongoing Stock Volatility - Yahoo Finance
A Fresh Look at ImmunityBio (IBRX) Valuation After Recent Share Rally - Yahoo Finance
ImmunityBio (IBRX) Soars 10.8% Ahead of Health Conferences - Insider Monkey
ImmunityBio Skyrockets on Positive Trial Results and Sales Growth - StocksToTrade
ImmunityBio Boosts Outlook with Strong Revenue Growth and Clinical Advances - timothysykes.com
ImmunityBio’s Immunotherapy Focus Boosts Market Expectations - StocksToTrade
ImmunityBio Gains Momentum with Strong ANKTIVA Sales and Clinical Advances - timothysykes.com
10 Stocks Racking Up Big Gains - Insider Monkey
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):